Radiopharm Theranostics Limited, a biotech company operating within the health care sector, has recently garnered attention for its strategic initiatives in the development of radiopharmaceutical products. Based in Carlton South, Australia, the company is dedicated to addressing high unmet medical needs through innovative diagnostic and therapeutic solutions. With a global customer base, Radiopharm Theranostics is making significant strides in the oncology field, particularly with its focus on radiopharmaceuticals for solid-tumour indications.
As of March 19, 2026, the company’s close price stood at 0.02 AUD, with a 52-week high of 0.04 AUD recorded on October 6, 2025, and a low of 0.017 AUD on December 9, 2025. The market capitalization of Radiopharm Theranostics is valued at 47,298,988 AUD, reflecting its position within the biotech landscape.
In a recent development, Radiopharm Theranostics filed a Form 6-K with the U.S. Securities and Exchange Commission on March 19, 2026. This filing announced the company’s intention to present at the NWR Virtual Healthcare Conference scheduled for March 25, 2026. The presentation will be delivered by Riccardo Canevari, the CEO and Managing Director of Radiopharm Theranostics. This event marks a significant opportunity for the company to showcase its clinical-stage biopharmaceutical advancements, particularly in oncology radiopharmaceuticals.
The filing included an announcement from the Australian Securities Exchange and provided a link for registration to the conference. It is noteworthy that Radiopharm Theranostics is listed on both the ASX All Markets and NASDAQ, underscoring its prominence in the biotech sector. The company’s pipeline is robust, featuring Phase 1 and Phase 2 studies targeting several solid-tumour indications, which highlights its commitment to advancing cancer treatment options.
The report, signed by the company secretary on behalf of the board, did not include additional financial disclosures beyond the announcement of conference participation. This strategic move to present at the NWR Virtual Healthcare Conference is a testament to Radiopharm Theranostics’ ongoing efforts to engage with the global healthcare community and to further its mission of developing cutting-edge radiopharmaceutical solutions.
For those interested in learning more about Radiopharm Theranostics’ activities and offerings, further information is available on their website at www.radiopharmtheranostics.com . The company’s proactive approach in the biotech industry continues to position it as a key player in the development of innovative healthcare solutions.
